New protocol could reduce hepatitis C in the U.S. prison system by 95%
In the U.S. prison system, the prevalence of hepatitis C virus (HCV) infection is currently 10 times higher than the national average. And while new HCV treatment drugs are very effective, their high cost along with very limited healthcare budget in prisons impedes universal treatment in prisons.
Now, new research in the INFORMS journal Operations Research, has identified new protocols that could substantially decrease HCV infection in the U.S. prison system. Such guidelines for prioritizing the treatment of hepatitis C infections in the U.S. prison system would result in a significant improvement in health outcomes of incarcerated persons while simultaneously reducing new infections in the society. The study, “Prioritizing Hepatitis C Treatment in U.S. Prisons,” was conducted by researchers from the Georgia Institute of Technology, Duke University, Denison University, Emory University, and Harvard Medical School.
While the prevalence of HCV infection in the general population is only 1-2 percent, within the prison system the prevalence of antibodies to hepatitis C jumps to 17 percent. This is primarily due to the fact that many HCV-infected people are current or past injection drug users (IDU). Nearly 80 percent of all HCV transmissions are IDU-related transmissions, and most Americans who inject drugs have been incarcerated at some point during their lives.
Currently the biggest barrier to treating persons in prison with HCV is that while the newest medications have a higher than 95 percent cure rate (versus a 50 percent cure rate of previous treatments), the cost of treatment is outrageously high. When the new treatments were approved in 2015, their cost was $84,000 per treatment course. Since then, the prices have come down to around $25,000. However, even at this price, treating incarcerated persons could cost $3.3 billion. Because the healthcare budget is very limited, only 1-13 percent of HCV-infected persons in prison receive treatment currently.
Because of the cost/budget constraints, prisons often prioritize patients for HCV treatment. The current approach emphasizes liver stage, and often ignores other factors such as their risk of transmission, age, etc. The study’s authors identified a new protocol to prioritize treatment among HCV-infected persons in the prison population to optimize the effect of HCV treatment on overall society’s well-being. Their solution systematically considers factors including liver health state, remaining sentence length, propensity to inject drugs, age, disease progression over time, and reinfection rates.
“We found that by simultaneously considering health state, remaining sentence length, IDU status, and age in prioritization, decisions can lead to a significant decrease in hepatitis C infections among justice-involved persons,” said the authors.
This new system offers an alternative to the current controversial patient prioritization protocol, which focuses on liver status, or the level of scarring on the patient’s liver. “Ideally, prisons would be allocated enough resources to treat everyone infected,” said the authors, who included a public health physician-researcher, who has been working with incarcerated persons living with HCV since 1996. “In the meantime, this algorithm is designed to maximize the public health outcome of treatment.”
If implemented, their protocol could reduce hepatitis C in the U.S. prison system by as much as 95 percent. Over time, the impact not only to correctional health, but treatment costs would be significant.
“Due to the simplicity in implementing prioritization policy, our work is appealing to multiple stakeholders within the U.S. prison system, including medical directors and policy makers at the prisons,” continued the authors. “Ultimately, by reducing the prevalence of hepatitis C in the prison population, we are reducing the chances of persons spreading the disease in the general population once they return to society.”
